Frazier Life Sciences Management’s CG Oncology CGON Stock Holding History

Frazier Life Sciences Management’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-770,000	Closed	-$20M	–	48
2025 Q2	$20M	Hold	770,000	–	–	0.8%	26
2025 Q1	$18.9M	Hold	770,000	–	–	0.86%	25
2024 Q4	$22.1M	Hold	770,000	–	–	0.92%	23
2024 Q3	$29.1M	Hold	770,000	–	–	1.16%	23
2024 Q2	$24.3M	Hold	770,000	–	–	1.14%	23
2024 Q1	$33.8M	Buy	+770,000	New	+$31.4M	1.43%	22

Other funds holding CGON

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Frazier Life Sciences Management's CGON Position: Q3 2025 in Review

Frazier Life Sciences Management sold out of CG Oncology (CGON) in Q3 2025, closing a stake of 770,000 shares — an estimated $20M sold.

Frazier Life Sciences Management first reported a position in CGON in Q1 2024 and held it in 6 quarters. The position peaked at $33.8M in Q1 2024. 176 funds tracked by Wall St. Rank hold CGON as of Q3 2025.

Frazier Life Sciences Management reported no remaining CG Oncology position as of Q3 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 770,000 CG Oncology shares in Q3 2025, an estimated $20M.
Frazier Life Sciences Management first reported a position in CG Oncology in Q1 2024 and held it in 6 quarters.
Frazier Life Sciences Management's CG Oncology position peaked at $33.8M in Q1 2024.
176 funds tracked by Wall St. Rank held CG Oncology as of Q3 2025.

Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.